Chemours (CC) Tops Q1 EPS by 9c; Offers Guidance

Chemours (NYSE: CC) reported Q1 EPS of $0.05, $0.09 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.4 billion.

The Company continues to expect 2026 Net Sales to grow in the range of 3% to 5% over 2025, with Adjusted EBITDA between $800 million and $900 million. This outlook is supported by higher TSS and APM Performance Solutions demand, anticipated TT pricing momentum, and ongoing cost improvements in each business. Capital expenditures are anticipated to be between $275 million and $325 million, with overall Free Cash Flow Conversion above 20%, due to increased earnings and improvements in working capital throughout the year. This revised estimate now reflects the approximate $30 million estimated full year income tax cash outflow related to the expected proceeds to be distributed on the sale of land at the former Kuan Yin TiO2 site. As an update to previous expectations, the Company anticipates that these cash flow dynamics will produce a net leverage ratio of less than 3.8x by the end of 2026.

For earnings history and earnings-related data on Chemours (CC) click here.

You May Also Be Interested In

• Tesla Crash Into Texas Home Now Under Federal Safety Probe - WSJ
• Qualcomm (QCOM) PT Raised to $195 at BofA Securities
• Japan's Katayama, Us Treasury's Bessent Hold Online Talks, Source Says - Reuters